CN112778294A - 5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor - Google Patents

5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor Download PDF

Info

Publication number
CN112778294A
CN112778294A CN202110019871.8A CN202110019871A CN112778294A CN 112778294 A CN112778294 A CN 112778294A CN 202110019871 A CN202110019871 A CN 202110019871A CN 112778294 A CN112778294 A CN 112778294A
Authority
CN
China
Prior art keywords
substituted
synthesis
group
unsubstituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110019871.8A
Other languages
Chinese (zh)
Inventor
王景炳
谢玲芝
乔丹丹
D.达斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Anrui Pharmaceutical Co ltd
Original Assignee
Suzhou Anrui Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Anrui Pharmaceutical Co ltd filed Critical Suzhou Anrui Pharmaceutical Co ltd
Priority to CN202110019871.8A priority Critical patent/CN112778294A/en
Publication of CN112778294A publication Critical patent/CN112778294A/en
Priority to CN202110626578.8A priority patent/CN113321645A/en
Priority to PCT/CN2021/135715 priority patent/WO2022148196A1/en
Priority to CN202210018194.2A priority patent/CN114195771A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Abstract

The invention relates to 5-aminoisoxazole derivatives and their use in the preparation of multi-kinase inhibitors, 5-aminoisoxazole derivatives of formula I, their isotopic forms, stereoisomeric forms, tautomeric forms, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, hydrates, prodrugs, and polymorphs thereof. The invention relates to a process for the preparation of a compound of formula I, wherein A, B, R1、R2、W1、W2、W3、W4、W5、W6、W7、W8And Y is as described in the description. The compounds and pharmaceutical compositions thereof are multi-kinase inhibitors and are useful for the treatment of cancer and immune related diseases.

Description

5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor
Technical Field
The invention relates to the field of pharmaceutical preparations, in particular to a 5-aminoisoxazole derivative and application thereof in preparation of a multi-kinase inhibitor.
Background
Protein phosphorylation regulates various aspects of cellular function such as cell division, metabolism, motility, survival and apoptosis. Disruption of any phosphorylation alters cellular function and may lead to a number of diseases including cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases and metabolic diseases. Phosphorylation is catalyzed by kinases. Protein kinases transfer a gamma-phosphate group from ATP to various amino acid residues. Upon activation, the kinase phosphorylates either the tyrosine hydroxyl group (tyrosine kinase) or the serine or threonine hydroxyl group (serine/threonine kinase). Protein kinases play a vital role in signal transduction, cell differentiation, cell proliferation, cell cycle progression, and the like. Protein Tyrosine Kinases (PTKs) act primarily as growth factor receptors. PTKs with receptor activity are also known as Receptor Tyrosine Kinases (RTKs). RTKs are cell surface receptors that have an extracellular domain that selectively bind to and are activated by a variety of growth factors, such as Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), insulin-like growth factor (IGF).
Angiogenesis is a key process for the growth of solid cancers. Cancer cells absorb necessary oxygen and nutrients from the surrounding environment. Due to the growth of solid tumors, low oxygen pressure, malnutrition, low pH, called hypoxia, occurs in regions 1-2 mm or more from the nearest blood vessel. Cancer cells respond to this stress by producing various angiogenic factors to stimulate angiogenesis and solid tumor growth of nearby vascular endothelial cells. Angiogenesis includes: (a) rupture of the basement membrane of the vessel wall; (b) migration and proliferation of vascular endothelial cell membranes; (c) and (4) forming blood vessels. Growth factors such as Fibroblast Growth Factor (FGF), platelet-derived growth factor (PDGF), Vascular Endothelial Growth Factor (VEGF) and the like have been observed as their mechanism of action. VEGF enhances microvascular permeability, sometimes referred to as vascular permeability factor. VEGF and VEGFR play a role in angiogenesis, the process of angiogenesis, and metastasis in solid tumors. VEGF is known to bind to three receptor tyrosine kinases, VEGFR1(FLT-1), VEGFR2(KDR), VEGFR3(FLT 4). VEGFR kinases have been used as targets for solid tumors, such as highly vascular renal, glioblastoma and liver cancers. Recently, angiogenesis inhibitors such as VEGFR2 or KDR directed against VEGF or inhibiting VEGFR kinase activity have become molecular targets for drug development (expeperotion Investigational Drugs 2003,12, 51-64).
FGFR, PDGFR, c-Met have been reported to be involved directly or indirectly in angiogenesis. Kinase inhibitors directed against these receptors are being investigated as therapeutic agents for cancer. FMS-like tyrosine kinase 3(FLT3), a RTK of the same family as PDGFR, is expressed in undifferentiated hematopoietic cells and signals hematopoietic cell proliferation and survival by binding to ligand FL expressed in bone marrow and other organs. Mutations in FLT3 are observed in about 30% of Acute Myeloid Leukemia (AML) and about 5% of myeloid language disorder syndrome (MDS). This variation leads to ligand-independent activation to signal aberrant proliferation and anti-apoptosis and is thought to be closely related to the progression of Acute Myeloid Leukemia (AML).
Multi-kinase inhibitors or broad-spectrum specific inhibitors are expected to exhibit high therapeutic effects by jointly inhibiting a few specific targets. Multi-kinase inhibitors are not able to selectively inhibit one kinase as a molecular target, and many multi-kinase inhibitors have been developed in recent years. In pharmaceutical chemistry methodologies, there are still many problems how to determine a specific set of kinases that can be targeted by a multi-kinase inhibitor to obtain good therapeutic effect and to suppress side effects. However, when considering heterogeneity and drug resistance of cancer cells, multi-kinase inhibitors are expected to be effective means for overcoming the above problems.
The multi-kinase inhibitor crizotinib has been shown to be effective in non-small cell lung Cancer (NSCLC) with altered MET exon 14 (Cancer discovmatch 1,2020,10(3), 337); multikinase inhibitors are used in the treatment of thyroid cancer (anker et el. int.j. mol. sci.2019,21(1), 10).
Sorafenib (Bay 43-9006) is a potent, oral multi-kinase inhibitor, being an inhibitor of VEGFR2, VEGFR3, PDGFRb, FLT3, c-Kit (IC50 ═ 90, 15, 20, 57, 58nM) and Raf-1 and B-Raf kinases (Wilhelm SM Cancer res.2004, 64, 7099-. Sorafenib is used to treat hepatocellular carcinoma (HCC), renal cancer and some type of thyroid cancer that have spread to other parts of the body. However, sorafenib has problems of high lipophilicity and low water solubility due to high hydrophobicity and high lattice of the phenylurea skeleton. The low solubility in water is a serious problem, especially in the clinical development of oral drugs, which is likely to cause problems of decreased absorption, unstable action and tendency to accumulate due to inter-patient pharmacokinetic variations (Pharma Zeutische Indret trie 2002, 64(9), 985-.
Levatinib is an inhibitor of VEGFR receptors 1-3, FGFR1-4, PDGFRa and KIT. Recently, a randomized phase 3 clinical trial was completed on lenvatinib and sorafenib in patients with hepatocellular carcinoma who could not be resected by first line therapy, and Kudo et al reported a randomized phase 3 non-adverse efficacy trial. (Kudo et al, the Lancet,2018,391, 1163-1173). Lenvatinib is also an effective drug for the treatment of certain thyroid cancers.
In addition, patented multikinase inhibitors such as: WO-2019036367 (multikinase inhibitors and their use in reproductive and digestive tract fibrosis), WO2019133022 (multikinase inhibitors and their use in prostate hyperplasia and urinary tract diseases), WO-2019125798 (carbamate and urea compounds as multikinase inhibitors, WO-2018022437 (multikinase inhibitors and their use in ocular fibrosis), WO-2018148653 (multigene inhibitors of VEGF and TGF- β and their use), WO2015187818 (benzimidazole analogues and related methods), WO-2015128698 (substituted heterocyclic amine derivatives as multikinase inhibitors for the treatment of cancer), WO2009015368 (multikinase inhibitors for the treatment of cancer), JP-2013189458-a (multikinase inhibitors for the treatment of cancer) discloses compounds as multikinase inhibitors, and for the treatment of a number of kinase-mediated diseases it is therefore necessary to develop more novel multi-kinase inhibitors for the treatment of cancer.
Disclosure of Invention
In order to solve the technical problems, the invention aims to provide a 5-aminoisoxazole derivative and an application thereof in preparing a multi-kinase inhibitor, wherein the derivative can effectively inhibit kinase activities of FLT1, FLT3, FLT4, FGFR1-4, VEGFR2/KDR, PDGFRa, PDGFRb, cKit and the like.
The first purpose of the invention is to disclose a 5-amino isoxazole derivative, the structural formula of which is shown in the formula (I):
Figure BDA0002888117580000031
wherein:
a is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and the substituent on the substituted aryl or substituted heteroaryl is selected from substituted or unsubstituted C1-10Alkyl, substituted or unsubstituted C1-10One or more of alkoxy, halogen and nitrile group;
b is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a group of formula (II), substituted or unsubstituted saturated or unsaturated C3-10Cycloalkyl or a heteroatom substituted or unsubstituted 4-7 membered cyclic amine; wherein the content of the first and second substances,
the substituents on the substituted aryl or substituted heteroaryl are selected from C1-10Alkyl radical, C1-10One or more of alkoxy, carboxyl, ester group, sulfone group and sulfonamide group;
the group of formula (II) is as follows:
Figure BDA0002888117580000032
wherein R is3And R4Each independently selected from hydrogen and C1-10Alkyl radical, C1-10Alkoxy radical, C1-10Alkylamino radical or C1-6A hydroxyalkyl group;
or R3And R4Linked to form a ring to form a substituted C3-10Cycloalkyl radicals, substituted C3-10Cycloalkyl includes heteroatom-substituted cycloalkyl or a spiro carbocyclic ring containing NH and/or oxygen atoms;
4-7 membered cyclic amine substituted or unsubstituted by hetero atom is chiral molecule or achiral molecule;
R1selected from hydrogen, substituted or unsubstituted C1-10An alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; the substituents on the substituted aryl or substituted heteroaryl groups are selected from substituted or unsubstituted C1-10Alkyl, substituted or unsubstituted C1-10One or more of alkoxy, halogen and halogen;
R2selected from hydrogen, C1-3Alkyl, cyano, C1-3Fluoroalkyl or halogen;
W1、W2、W3、W4、W5、W6and W7Each being CH or N, satisfying the valence state, and at least W1、W2、W3、W4、W5、W6And W7One of them is N;
W8o, S, NH or NMe;
y is selected from a group of the following structural formula:
Figure BDA0002888117580000041
in the present invention, unless otherwise specified,
Figure BDA0002888117580000042
represents the site of attachment of the group.
Further, in the group A or B, the aryl group therein is C6-C9Aryl, heteroaryl including C with nitrogen and/or sulfur as hetero atoms4-C6A heteroaryl group.
Preferably, a is selected from the group of the following structural formulae:
Figure BDA0002888117580000043
further, B is selected from the group represented by formula (II):
Figure BDA0002888117580000044
wherein R is3And R4Each independently selected from hydrogen and C1-10Alkyl radical, C1-10Alkoxy radical, C1-6Alkylamino radical or C1-6A hydroxyalkyl group; alkylamino being a primary amineA radical or secondary amine radical; a 3-7 membered carbocyclic ring; 4-7 membered cyclic amines; 4-7 membered heteroatom substituted cyclic amine; chiral 5-7 membered amines; substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; substituted or unsubstituted piperazine, substituted or unsubstituted morpholine; a carbocyclic ring containing no heteroatoms, a carbocyclic ring containing heteroatoms, an unsaturated carbocyclic ring, a spirocyclic carbocyclic ring containing NH and oxygen atoms.
Preferably, B is selected from a group of the following formulae:
Figure BDA0002888117580000045
Figure BDA0002888117580000051
further, R1Selected from biphenyl or a group of the formula:
Figure BDA0002888117580000052
preferably, R2Selected from hydrogen, methyl, cyano, trifluoromethyl or halogen.
In some embodiments, a represents a six-membered aromatic ring and the 5-aminoisoxazole derivative has formula Ia, Ib, Ic and pharmaceutically acceptable salts and solvates thereof:
Figure BDA0002888117580000053
wherein, B, R1And R2As described above, R3Selected from the group consisting of hydrogen, methyl, phenyl and 4-chlorophenyl.
In some embodiments, a represents a six-or five-membered heterocyclic ring, and the 5-aminoisoxazole derivative compound has the formula Id, Ie, If, Ig and pharmaceutically acceptable salts and solvates thereof:
Figure BDA0002888117580000061
wherein, B, R1、R2And W6As described above.
Further, the structural formula of the 5-amino isoxazole derivative is shown as one of formulas I-1 to I-86:
Figure BDA0002888117580000062
Figure BDA0002888117580000071
Figure BDA0002888117580000081
Figure BDA0002888117580000091
Figure BDA0002888117580000101
the second purpose of the invention is to disclose a pharmaceutical preparation, which comprises the 5-aminoisoxazole derivative shown in the formula (I), or pharmaceutically acceptable salt, stereoisomer, deuterium substituted derivative, hydrate or solvate thereof, and other pharmaceutically acceptable carriers.
Further, the pharmaceutical formulation is administered alone or in combination with other therapeutic agents.
A third object of the present invention is to disclose the use of a 5-aminoisoxazole derivative represented by formula (I), or a pharmaceutically acceptable salt, stereoisomer, deuterium substituted derivative, hydrate or solvate thereof, for the preparation of a medicament for treating a condition which can be ameliorated or prevented by inhibiting kinase activity or inhibiting proliferation of a cell or enzyme; the kinases comprise one or more of FLT1, FLT3, FLT4, FGFR1-4, VEGFR2/KDR, PDGFRa, PDGFRb, cKit and the like.
In the above application, the method comprises administering a therapeutically effective amount of the pharmaceutical preparation containing the 5-aminoisoxazole derivative shown in the formula (I) to a subject.
Further, the disorder is selected from cancer and/or immune related diseases, preferably one or more of liver cancer, bone marrow cancer, gastrointestinal stromal tumor (GIST), colon cancer, kidney cancer, lung cancer, breast cancer, kidney cancer, glioblastoma and Irritable Bowel Syndrome (IBS).
Further, the drug is administered orally, parenterally, intravenously, or transdermally.
By the scheme, the invention at least has the following advantages:
the invention discloses a 5-amino isoxazole derivative shown in a formula (I), which can be used for preparing medicaments for improving or preventing diseases or inhibiting cell or enzyme proliferation by inhibiting kinase activity and provides a new direction for treating cancers and immune related diseases.
The foregoing is a summary of the present invention, and in order to provide a clear understanding of the technical means of the present invention and to be implemented in accordance with the present specification, the following is a preferred embodiment of the present invention and is described in detail below.
Detailed Description
The following examples are given to further illustrate the embodiments of the present invention. The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
In the following examples of the present invention, Biotage SP4 was used for column chromatography. Solvent removal was performed using a Buchi rotary evaporator or a Genevac centrifugal evaporator. Preparation of LC/MS A C18 column under acidic mobile phase conditions was run using a Waters autosifier and a 19X 100mm XTerra 5 micron MS. Nuclear magnetic resonance spectroscopy was recorded using a warian 400MHz spectrometer. When the term "inert" is used to describe a reactor (e.g., reaction vessel, flask, glass reactor, etc.), it means that the air in the reactor has been replaced with an inert gas that is substantially free of water or dry (e.g., nitrogen, argon, etc.).
The following examples refer to the following abbreviations in english and the corresponding chinese names:
HATU: 2- (7-azabenzotriazol-1-yl) -N, N' -tetramethyluramino hexafluorophosphate; DPCI: n, N' -diisopropylcarbodiimide; DIEA: n, N-diisopropylethylamine; TEA: triethylamine; DMAP: dimethylaminopyridine; DMF: n, N-dimethylformamide; NMP: n-methylpyrrolidine; THF: tetrahydrofuran; DCM: dichloromethane; TFA: trifluoroacetic acid; DMA: n, N-dimethylacetamide; TLC: thin layer chromatography; TMOF: trimethyl orthoformate; PTSA: p-toluenesulfonic acid; NIS: n-iodosuccinimide; eq: equivalent weight; mmol: millimole; mol: molar ratio; mL: ml; l: lifting; MHz: megahertz; δ: chemical shift; DMSO-d 6: deuterated dimethyl sulfoxide; hrs, hr, h: hours; ms: mass spectrometry; m/z: mass to charge ratio.
The following starting materials or intermediates are commercially available or can be prepared according to known literature procedures:
Figure BDA0002888117580000121
Figure BDA0002888117580000131
the synthetic route for compounds 6a-6j is as follows:
Figure BDA0002888117580000132
wherein, the structural formula of 2a-l is as follows:
Figure BDA0002888117580000133
wherein 2- (4- (5-bromo-1H-benzo [ d ] imidazol-1-yl) phenyl) acetic acid (6a) is prepared according to the above scheme as follows:
step 1: adding the compound 2a (6.1g, 34.3mmol) to a mixed solution of the compound 1(5.0g, 22.8mmol) and DMA (60ml) at room temperature, heating the mixture to 145-160 ℃, stirring for 8-10h until the TLC monitoring reaction is completed, cooling the reaction mixture to room temperature, washing the organic phase with water and brine respectively, drying over anhydrous sodium sulfate and evaporating to dryness to obtain a crude product, purifying by silica gel column chromatography to obtain the product 3a (6.51g, yield: 75.6%),
1H NMR(DMSO-d6,400MHz):δ＝9.42(s,1H),8.21(d,1H),7.61(dd,1H),7.30(dd,4H),7.09(d,1H),4.12-4.07(m,2H),3.68(s,2H),1.22-1.18(t,3H)。
step 2: to a solution of compound 3a (6.5g, 17.2mmol), Zn powder (11.2g, 171.2mmol) in ethanol (100mL) at 0 deg.C was added dropwise a mixed solution of AcOH (7.2g, 120.4mmol) in EtOH (8mL) over about 1 hour, the reaction mixture was stirred at 0 deg.C for 3-8 hours, the reaction was monitored by TLC until compound 3a was completely consumed, the reaction mixture was warmed to room temperature, ethyl acetate (10 mL. times.3) was extracted, the organic phase was washed with water and brine, respectively, anhydrous Na2SO4Dried and evaporated to dryness to give crude 4a (5.7g, yield: 95.2%, product 4a was sufficiently pure to be used in the next synthesis step without further purification).
1HNMR(DMSO-d6,400MHz):δ＝7.09(s,1H),7.04-7.02(m,2H),6.91-6.89(m,2H),6.70-6.68(m,2H),6.65-6.63(m,1H),5.04(s,2H),4.08-4.03(m,2H),3.49(s,2H),1.23-1.17(t,3H)。
And step 3: to a mixture of 4a (5.7g, 16.4mmol) and TMOF (13.0g, 122.8mmol) was added PTSA (280 mg, 1.64mmol) at room temperature and stirred at this temperature for 2-5h until TLC monitoring showed complete consumption of compound 4a, excess TMOF and other volatiles were distilled off, extracted with ethyl acetate (10 ml. times.3), the organic phase was washed with water and brine, respectively, anhydrous Na2SO4Dried and evaporated to dryness to give crude 5a (5.9g, yield: 100%, product 5a sufficiently pure to be used in the next synthesis step without further purification).
1H NMR(DMSO-d6,400MHz):δ＝8.01(s,1H),8.00(s,1H),7.51-7.49(m,2H),7.45-7.41(m,4H),4.23-4.17(m,2H),3.72(s,2H),1.29-1.27(t,3H)。
And 4, step 4: to compound 5a (3.0g, 8.38mmol) in MeOH (30ml) at room temperature was added NaOH (1.0g, 25.1mmol) in dropwise fashion in H2O (10ml) solution and stirred for 2-5h until TLC monitoring the reaction showed complete consumption of compound 5 a. The mixture was cooled to room temperature, the pH was adjusted to 1 with 2N Cl, and solid 6a (2.5g, yield: 91.1%) was collected by filtration.
1H NMR(DMSO-d6,400MHz):δ＝8.61(s,1H),7.99(d,J＝2.0Hz,1H),7.63-7.61(m,2H),7.59-7.57(m,1H),7.53-7.48(m,2H),7.47-7.45(m,1H),3.71(s,2H)。
The intermediate 6b-l was prepared according to the same procedure and has the following structural formula:
Figure BDA0002888117580000141
the intermediate 6b-l names and characterization results are shown in table 1:
TABLE 1 intermediates 6b-l
Figure BDA0002888117580000142
Figure BDA0002888117580000151
The synthetic route for compound 8 is as follows:
Figure BDA0002888117580000152
following the above scheme, the specific steps for compounds 8a-8ii are as follows:
mixing compound 6(0.5mmol) with compound 7(0.6mmol, 1.2eq), HATU (0.55mmol, 1.1eq), Et3A mixed solution of N (1.5mmol, 3eq) in THF (10ml) will be stirred at room temperature for 2-5 hours until TLC monitoring of the reaction shows complete consumption of compound 6. The residue obtained by distilling off THF is diluted with ethyl acetateReleasing, washing with water and brine respectively, and washing the organic phase with anhydrous Na2SO4Drying and evaporating to dryness to obtain crude product, and purifying with silica gel column chromatography (eluting with dichloromethane and methanol) to obtain compound 8 with moderate to good yield (45-85%). The structural formula of the intermediate 8a-8ee is as follows in sequence:
Figure BDA0002888117580000161
Figure BDA0002888117580000171
the names and characterization results for intermediates 8a-8ii are shown in table 2:
TABLE 2 intermediates 8a-8ii
Figure BDA0002888117580000172
Figure BDA0002888117580000181
Figure BDA0002888117580000191
Figure BDA0002888117580000201
The title compounds of examples 1-19 were prepared according to the following suzuki reaction scheme:
Figure BDA0002888117580000202
wherein compounds 9, 10 comprise the following structural formulae:
Figure BDA0002888117580000203
the specific steps of the suzuki reaction are as follows:
under nitrogen protection, compound 8(0.77mmol), boric acid derivative 9 or borate derivative 10(0.93mmol), Pd (dppf) Cl2(28mg，0.039mmol)、Na2CO3(1.2mL, 2.32mmol, 2N aq.) and dioxane (3mL) were stirred at 65-90 deg.C for 6-10 hours until TLC monitoring of the reaction indicated complete consumption of Compound 8, the reaction mixture was cooled to room temperature, extracted with ethyl acetate (15 mL. times.3), the organic phase was washed with water and brine, respectively, anhydrous Na2SO4Drying and evaporating to dryness to obtain crude product, and purifying by preparative thin layer chromatography to obtain medium to good yield. Specifically, the characterization results of each example and the target product are as follows:
EXAMPLE 1 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (isoxazol-5-yl) acetamide (I-1)
The intermediate 8a was used to react with the N-Boc pyrazole borate derivative (10c) to give the desired product. And (3) product characterization results:
MS:m/z:385.1(M+H)+。
EXAMPLE 2 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3-methylisoxazol-5-yl) acetamide (I-2)
The intermediate 8b and the N-Boc pyrazole borate derivative (10c) were used to give the desired product.
MS:m/z:399.2(M+H)+。
EXAMPLE 3 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-3)
The target product was prepared using intermediate 8c and N-methylpyrazole boronic acid (9 b).
MS:m/z:455.2(M+H)+；1H NMR(DMS:O-d6,400MHz):δ＝11.87(s,1H),8.53(s,1H),8.17(s,1H),7.97(s,1H),7.92(s,1H),7.68-7.65(m,2H),7.59-7.56(m,4H),6.23(s,1H),3.88(s,3H),3.83(s,2H),1.25(s,9H)；13C NMR(DMS:O,100MHz):δ＝172.9,167.9,161.4,145.0,144.0,136.5,135.2,134.9,132.1,131.3,128.1,127.9,123.8,122.8,121.8,116.3,111.4,86.4,42.1,32.4,29.4。
EXAMPLE 4 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (tert-butyl) isoxazol-5-yl) acetamide (I-4)
The intermediate 8c and N-Boc pyrazole borate derivative (10c) were used to prepare the target product.
MS:m/z:441.2(M+H)+；1H NMR(DMS:O,400MHz):δ＝12.90(s,1H),11.86(s,1H),8.52(s,1H),8.25(s,1H),8.03(s,1H),7.99(s,1H),7.68-7.65(m,2H),7.59-7.55(m,4H),6.23(s,1H),3.83(s,2H),1.25(s,9H)；13C NMR(DMS:O,100MHz):δ＝172.9,167.9,161.4,145.1,144.0,136.7,135.3,134.9,132.0,131.3,128.3,125.7,123.9,122.1,121.9,116.4,111.4,86.4,49.1,42.1,32.4,29.5。
EXAMPLE 5 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3-isopropylisoxazol-5-yl) acetamide (I-5)
The desired product was prepared using intermediate 8d and N-methylpyrazole boronic acid (9 b).
1HNMR(DMS:O-d6,400MHz):δ＝11.87(s,1H),8.53(s,1H),8.17(s,1H),7.97(s,1H),7.92(s,1H),7.67-7.65(m,2H),7.58-7.55(m,4H),6.18(s,1H),3.87(s,3H),3.83(s,2H),2.94-2.90(m,1H),1.19(d,6H)；13C NMR(DMS:O-d6,100MHz):δ＝170.3,168.0,161.4,144.9,144.0,136.4,135.2,134.9,132.0,131.3,128.0,127.9,127.5,123.8,122.8,121.8,116.6,116.2,111.4,86.6,42.1,26.7,21.7.MS:m/z:441.2(M+H)+。
EXAMPLE 6 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (trifluoromethyl) isoxazol-5-yl) acetamide (I-6)
The intermediate 8e and the N-Boc pyrazole borate derivative (10c) were used to prepare the desired product.
MS:m/z:453.1(M+H)+。
EXAMPLE 7 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3-propylisoxazol-5-yl) acetamide (I-7)
The target product was prepared using intermediate 8f and N-methylpyrazole boronic acid (9 b).
1H NMR(DMS:O-d6,400MHz):δ＝11.85(s,1H),8.53(s,1H),8.16(s,1H),7.98(s,1H),7.91(s,1H),7.67-7.65(m,2H),7.59-7.55(m,4H),6.15(s,1H),3.88(s,3H),3.84(s,2H),2.53-2.51(m,2H),1.62-1.59(m,2H),0.91-0.87(t,3H)；13C NMR(DMS:O-d6,100MHz):δ＝167.9,165.0,161.4,144.8,144.1,136.5,135.2,134.9,132.0,131.3,128.1,128.0,123.9,122.8,121.8,116.2,111.5,88.1,42.1,28.0,21.3,13.9；MS:m/z:441.2(M+H)+。
EXAMPLE 8 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3-cyclopropylisoxazol-5-yl) acetamide (I-8)
The target product was obtained using intermediate 8g and N-Boc pyrazole borate derivative (10 c).
MS:m/z:425.2(M+H)+。
EXAMPLE 9 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3, 4-dimethylisoxazol-5-yl) acetamide (I-9)
The intermediate 8h and the N-Boc pyrazole borate derivative (10c) were used to prepare the desired product.
MS:m/z:413.2(M+H)+。
EXAMPLE 10 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (4-cyano-3-methylisoxazol-5-yl) acetamide (I-10)
The intermediate 8i and the N-Boc pyrazole borate derivative (10c) were used to give the desired product.
MS:m/z:424.1(M+H)+。
EXAMPLE 11 Synthesis of 2- (4- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3-phenylisoxazol-5-yl) acetamide (I-11)
The intermediate 8j and N-methylpyrazole boronic acid (9b) were used to obtain the desired product.
MS:m/z:475.2(M+H)+；1H NMR(DMS:O-d6,400MHz):δ＝12.09(s,1H),8.54(s,1H),8.18(s,1H),7.97(s,1H),7.92(s,1H),7.85-7.84(m,2H),7.69-7.67(m,2H),7.61-7.59(m,3H),7.56-7.54(m,1H),7.51-7.49(m,3H),6.74(s,1H),3.90(s,2H),3.87(s,3H)；13C NMR(DMS:O-d6,100MHz):δ＝168.1,163.1,162.5,145.0,144.1,136.5,135.2,134.8,132.0,131.4,130.7,129.5,129.2,128.0,127.9,126.9,123.9,122.8,121.8,116.2,111.5,86.5,42.1。
EXAMPLE 12 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (2-chlorophenyl) isoxazol-5-yl) acetamide (I-12)
The intermediate 8k and N-Boc pyrazole borate derivative (10c) were used to give the desired product.
MS:m/z:495.1(M+H)+。
EXAMPLE 13 Synthesis of N- (3- (4-chlorophenyl) isoxazol-5-yl) -2- (4- (5- (1-methyl-1H-pyrazol) -4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-13)
The desired product was obtained using intermediate 8l and N-methylpyrazole boronic acid (9 b).
EXAMPLE 14 Synthesis of N- (3- (4-fluorophenyl) isoxazol-5-yl) -2- (4- (5- (1-methyl-1H-pyrazol-ol) -4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-14)
This compound was prepared according to general scheme 3 using intermediate 8m and N-methylpyrazole boronic acid (9b) to afford the desired product.
MS:m/z:493.2(M+H)+。
EXAMPLE 15 Synthesis of 2- (4- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (m-tolyl) isoxazol-5-yl) acetamide (I-15)
The intermediate 8N and N-methylpyrazole boronic acid (9b) were used to give the desired product.
MS:m/z:489.2(M+H)+。
EXAMPLE 16 Synthesis of N- (3- (3-methoxyphenyl) isoxazol-5-yl) -2- (4- (5- (1-methyl-1H) -pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-16)
The intermediate 8o and N-methylpyrazole boronic acid (9b) were used to give the desired product.
MS:m/z:505.2(M+H)+。
EXAMPLE 17 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (3- (trifluoromethyl) phenyl) isoxazol-5-yl) acetamide (I-17)
The intermediate 8p and the N-Boc pyrazole borate derivative (10c) were used to give the desired product.
MS:m/z:529.2(M+H)+。
EXAMPLE 18 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (3-bromophenyl) isoxazol-5-yl) acetamide (I-18)
The intermediate 8q and N-Boc pyrazole borate derivative (10c) were used to give the desired product.
MS:m/z:539.1(M+H)+。
EXAMPLE 19 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (pyridin-3-yl) isoxazol-5-yl) acetamide (I-19)
The intermediate 8r and N-Boc pyrazole borate derivative (10c) were used to give the desired product.
MS:m/z:462.2(M+H)+。
EXAMPLE 20 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] [1,2,3] triazol-1-yl) phenyl) acetamide (I-20)
Figure BDA0002888117580000241
Step 1: to a mixture of compound 4a (3.0g, 8.59mmol), HCl (5N, 10ml) and AcOH (10ml) NaNO was slowly added dropwise at-5 ℃ to 0 ℃2(0.89g, 12.9mmol) of H2O (8ml) solution, after the addition was complete, stirring was continued at room temperature for 1-3h until TLC monitoring of the reaction indicated complete consumption of compound 4a, the reaction mixture was poured into an ice bath, the system pH was adjusted to 7 with 2N NaOH, and extraction was carried out with ethyl acetate (20 ml. times.3). The organic phase was washed with water and brine, respectively, anhydrous Na2SO4Drying and evaporation to dryness gave compound 11(2.6g, yield: 84%).
1H NMR(DMSO-d6,400MHz):δ＝8.51-8.50(m,1H),7.93-7.91(m,1H),7.85-7.83(m,2H),7.80-7.77(m,1H),7.60-7.58(m,2H),4.15-4.10(m,2H),3.85(s,2H),1.24-1.20(t,3H).
Step 2:under nitrogen protection, compound 11(500mg, 1.39mmol) was reacted with N-methylpyrazole boronic acid (9b) (261mg, 2.09mmol), Pd (dppf) Cl2(51mg，0.069mmol)、Na2CO3(2.1mL, 4.18mmol, 2N aq.) in dioxane (5mL) was stirred at 70-80 deg.C for 2h until TLC monitoring the reaction showed complete consumption of Compound 11, the reaction mixture was cooled to room temperature, ethyl acetate (20 mL. times.3) was extracted, the organic layer was washed with water and brine, anhydrous Na2SO4Drying to dryness to obtain crude product, and purifying by column chromatography to obtain compound 12(451mg, yield: 90%).
1H NMR(DMSO-d6,400MHz):δ＝8.39-8.37(m,1H),8.33(s,1H),8.06(s,1H),7.92-7.90(m,2H),7.88-7.85(m,2H),7.60-7.58(m,2H),4.16-4.11(m,2H),3.90(s,3H),3.85(s,2H),1.24-1.21(t,3H).
And step 3: to compound 12(400mg, 1.11mmol) in MeOH (4ml) and H2NaOH (88mg, 2.22mmol) was added to a mixed solvent of O (1ml), warmed to 80 ℃ and stirred for 2-6h until TLC monitoring the reaction showed complete consumption of compound 6i, the reaction mixture was cooled to room temperature, adjusted to pH 1 with 2N HCl, filtered and collected solid compound 13(245mg, yield: 66%).
1H NMR(DMSO-d6,400MHz):δ＝8.36-8.33(m,2H),8.06(s,1H),7.93-7.90(m,2H),7.86-7.84(m,2H),7.60-7.57(m,2H),3.90(s,3H),3.76(s,2H).
And 4, step 4: compound 13(120mg, 0.36mmol) was reacted with compound 7c (61mg, 0.43mmol), HATU (205mg, 0.54mmol), Et at room temperature3A solution of N (109mg, 1.08mmol) in THF (5ml) was stirred for 1-3h until TLC monitoring showed complete consumption of starting material, THF was evaporated and extracted with ethyl acetate (20 ml. times.3), the organic phase was washed with water and brine, respectively, anhydrous Na2SO4Dried and evaporated to dryness to give crude product, purified by preparative TLC to give the desired product I-20(100 mg).
1H NMR(DMSO-d6,400MHz):δ＝11.31(s,1H),8.34(d,2H),8.05(s,1H),7.91-7.85(m,4H),7.63(d,2H),6.60(s,1H),3.90(s,3H),3.84(s,2H),1.28(s,9H)。
Example 21: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (6- (1-methyl-1H-pyrazol-4-yl) -3H-imidazo [4,5-c ] pyridin-3-yl) phenyl) acetamide (I-21)
Figure BDA0002888117580000251
Intermediate 19 was synthesized according to the method for synthesizing intermediates 6b to 6l, and then the target product was prepared using intermediate 19 and N-methylpyrazole boronic acid (9 b).
MS m/z:456.2(M+H)+。
EXAMPLE 22 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (2- (1-methyl-1H-pyrazol-4-yl) -7H-purin-7-yl) phenyl) acetamide (I-22)
Figure BDA0002888117580000252
Step 1: under nitrogen protection, compound 20(500mg, 2.53mmol), compound 21(750mg, 3.79mmol), Pd2(dba)3(116mg，0.13mmol)，XantPhos(295mg，0.51mmol)，Cs2CO3(2.5g, 7.58mmol) in toluene (5mL) was heated to 65-90 ℃ and stirred for 8-12h until TLC monitoring the reaction showed complete consumption of compound 20, the reaction mixture was cooled to room temperature, extracted with ethyl acetate (30 mL. times.3), the organic phase was washed with water and brine, respectively, anhydrous Na2SO4Drying and evaporation to dryness gave crude product, which was purified on silica gel column to give product 22(415mg, yield: 46%).
Step 2: to compound 22(415mg, 1.15mmol) in MeOH (6ml) and H2To a mixed solution of O (2ml) was added NaOH (92mg, 2.30mmol) and the mixture was stirred at 80 ℃ for 2-6 hours until TLC monitoring of the reaction showed complete consumption of Compound 22, the mixture was cooled to room temperature, adjusted to pH 1 with 2N HCl, filtered and the solid 23 was collected (320mg, yield: 83%).
And step 3: a mixture of compound 23(300mg, 0.90mmol), compound 7c (152mg, 1.08mmol), HATU (378mg, 0.99mmol), Et3A solution of N (274mg, 2.71mmol) in THF (8mL) was stirred at room temperature for 2-6h until TLC monitoring of the reaction indicated complete consumption of starting material.The THF was evaporated off, extracted with ethyl acetate (20 mL. times.3), the organic phase was washed with water and brine, respectively, anhydrous Na2SO4Dried and evaporated to dryness to give a crude product, which was purified by column chromatography to give 24(318mg, yield: 78%).
And 4, step 4: under nitrogen protection, compound 24(125mg, 0.28mmol), N-methylpyrazole boronic acid (9b) (52mg, 0.41mmol), Pd (dppf) Cl2(40mg，0.055mmol)，Na2CO3(0.3mL, 0.55mmol, 2N aq.) in dioxane (5mL) was stirred at 70-80 ℃ for 3h until TLC monitoring of the reaction indicated complete consumption of compound 24, the reaction mixture was cooled to room temperature, extracted with ethyl acetate (20 mL. times.3), the organic phase was washed with water and brine, respectively, anhydrous Na2SO4Drying and evaporating to dryness to obtain crude product, and purifying by preparative TLC to obtain target product I-22(62mg, yield: 49%)
MS m/z:457.2(M+H)+。
EXAMPLE 23 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (6- (1-methyl-1H-pyrazol-4-yl) pyrazoline [1,5-a ] pyridin-3-yl) phenyl) acetamide (I-23)
Figure BDA0002888117580000261
Step 1: under nitrogen protection, compound 25(500mg, 2.55mmol), N-methylpyrazole boronic acid (9b) (482mg, 3.83mmol), Pd (dppf) Cl2(93mg，0.13mmol)，Na2CO3A solution of dioxane (8mL) (3.8mL, 7.65mmol, 2N aq.) was stirred at 70-80 deg.C for 2h until TLC monitoring of the reaction indicated complete consumption of compound 25, the reaction mixture was cooled to room temperature and extracted with ethyl acetate (20 mL. times.3). The organic phase was washed with water and brine, respectively, anhydrous Na2SO4Dried and evaporated to dryness to give a crude product, which was purified with silica gel column to give compound 26(320mg, yield: 63%).
Step 2: to a solution of compound 26(300mg, 1.51mmol) in DMF (5mL) was added NIS (375mg, 1.67mmol) and stirred at room temperature for 3-5h until TLC monitoring of the reaction showed complete consumption of compound 26 and extraction with ethyl acetate (20 mL. times.3). The organic phase is respectively treated with water and brineWashing with anhydrous Na2SO4Dried and evaporated to dryness to give a crude product, which was purified with silica gel column to give compound 27(410mg, yield: 82%).
And step 3: under nitrogen protection, compound 27(410mg, 1.27mmol), compound 28(551mg, 1.89mmol), Pd (dppf) Cl2(46mg，0.063mmol)、Na2CO3(1.9mL, 3.79mmol, 2N aq.) in dioxane (10mL) was stirred at 70-80 ℃ for 4h until TLC monitoring of the reaction showed complete consumption of compound 27, the reaction mixture was cooled to room temperature, ethyl acetate (20 mL. times.3) was extracted, the organic phase was washed with water and brine, respectively, anhydrous Na2SO4Dried and evaporated to dryness to give a crude product, which was purified with silica gel column to give compound 29(330mg, yield: 72%).
And 4, step 4: to mixture 29(330mg, 0.92mmol) in MeOH (4ml) and H2To a mixed solution of O (1ml) was added NaOH (73mg, 1.83mmol) and stirred at 80 ℃ for 2-6 hours until TLC monitoring the reaction showed complete consumption of compound 29, the reaction mixture was cooled to room temperature, adjusted to pH 1 with 2N HCl, filtered and the solid was collected to give compound 30(230mg, yield: 76%).
And 5: a mixture of 30(110mg, 0.33mmol), 7C (55mg, 0.40mmol), HATU (138mg, 0.36mmol) and Et3N (101mg, 0.99mmol) in THF (5mL) was stirred at room temperature for 1-3h until TLC monitoring showed complete consumption of starting material, the solvent THF was evaporated, ethyl acetate (20 mL. times.3) was extracted, the organic layer was washed with water and brine, respectively, anhydrous Na2SO4Drying and evaporating to dryness to obtain crude product, and purifying by preparative TLC to obtain product I-23(75 mg).
MS m/z:455.2(M+H)+。
EXAMPLE 24 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) pyridin-2-yl) acetamide (I-24)
The desired product was obtained according to the method for the synthesis of I-1 using intermediate 8s and N-methylpyrazole boronic acid (9 b).
MS m/z:456.2(M+H)+。
EXAMPLE 25 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) pyrazin-2-yl) acetamide (I-25)
The desired product was obtained according to the method for synthesizing I-1 using intermediate 8t and N-methylpyrazole boronic acid (9 b).
MS m/z:457.2(M+H)+。
EXAMPLE 26 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (2- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) thiazol-5-yl) acetamide (I-26)
The desired product was obtained according to the method for synthesizing I-1 using intermediate 8u and N-methylpyrazole boronic acid (9 b).
MS m/z:462.2(M+H)+。
EXAMPLE 27 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (2- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) thiazol-4-yl) acetamide (I-27)
The desired product was prepared according to the procedure for the synthesis of I-1, using intermediate 8v and N-methylpyrazole boronic acid (9 b).
MS m/z:462.2(M+H)+。
EXAMPLE 28 Synthesis of 2- (4- (5- (2-oxo-6-azaspiro [3.3] heptane 6-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (tert-butyl) isoxazol-5-yl) acetamide 1H-benzo [ d ] imidazol-1-yl) benzamide (I-28)
Figure BDA0002888117580000281
Under the protection of nitrogen, compound 8c (1.11mmol), amine 31(1.33mmol) and Pd2(dba)3(202mg，0.22mmol)、Xantphos(128mg，0.22mmol)、tBuONa (212mg, 2.21mmol) in toluene (5ml) mixed solution was stirred at 65-90 ℃ for 8-12h until TLC monitoring of the reaction showed complete consumption of compound 8c, the reaction mixture was cooled to room temperature, ethyl acetate (30 ml. times.3) was extracted, the organic phase was washed with water and brine, respectively, anhydrous Na2SO4Drying and evaporating to dryness to obtain a crude product, and purifying by preparative TLC to obtain a product. The structure of the compound is shown by1HNMR、13CNMR was performed for characterization.
Compound I-28 was prepared according to the above route, specifically from intermediate 8c and 2-oxa-6-aza-spiro [3, 3]]And (3) preparing heptane. The characterization result is as follows: MS M/z 472.2(M + H)+；1H NMR(400MHz,DMSO-d6)δ11.89(s,1H),8.39(s,1H),7.60(d,J＝8.4Hz,2H),7.53(d,2H),7.46(d,J＝8.7Hz,1H),6.75(d,J＝1.8Hz,1H),6.53(dd,1H),6.22(s,1H),4.74(s,4H),3.98(s,4H),3.84–3.75(m,2H),1.24(s,9H).
EXAMPLE 29 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -1- (4- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) cyclopropane-1-carboxamide (I-29)
The desired product was prepared following a similar procedure to that for the synthesis of I-1, using intermediate 8x and N-methylpyrazole boronic acid (9 b).
MS:m/z:481.2(M+H)+。
EXAMPLE 30 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2, 2-difluoro-2- (4- (5- (1-methyl) -1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-30)
The desired product was prepared following a similar procedure to that for the synthesis of I-1, using intermediate 8y and N-methylpyrazole boronic acid (9 b).
MS:m/z:491.2(M+H)+。
EXAMPLE 31 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5-morpholin-1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-31)
Following a similar procedure to that for the synthesis of I-28, intermediate 8c and morpholine were used to give the desired product.
MS:m/z:460.2(M+H)+；1H NMR(400MHz,DMSO-d6)δ11.90(s,1H),8.45(s,1H),7.63(d,J＝8.3Hz,2H),7.54(d,J＝8.4Hz,2H),7.51(d,J＝9.0Hz,1H),7.25(s,1H),7.10(dd,J＝9.1,2.0Hz,1H),6.22(s,1H),3.81(s,2H),3.80–3.72(m,4H),3.15–3.07(m,4H),1.24(s,9H).。
EXAMPLE 32 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (piperazin-1-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-32)
The desired product was obtained in a similar manner to the synthesis of I-28, using intermediate 8c and 1-tert-butoxycarbonylpiperazine. MS M/z 459.2(M + H)+.
EXAMPLE 33 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- ((2-hydroxy-2-methylpropyl) amino) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-33)
The desired product was obtained in a similar manner to that for the synthesis of I-28, using intermediate 8c and 1-amino-2-methylpropan-2-ol.
MS:m/z:462.2(M+H)+。
EXAMPLE 34 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (4-hydroxypiperidin-1-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-34)
The desired product was obtained in analogy to the synthesis of I-28, using intermediate 8c and piperidin-4-ol.
MS:m/z:474.2(M+H)+。
EXAMPLE 35 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (piperidin-1-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-35)
The desired product was prepared following a procedure analogous to that for the synthesis of I-28, using intermediate 8c and piperidine.
MS:m/z:458.2(M+H)+。
EXAMPLE 36 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5-thiomorpholin-1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-36)
The desired product was obtained in a similar manner to that for the synthesis of I-28, using intermediate 8c and thiomorpholine.
MS:m/z:476.5(M+H)+。
EXAMPLE 37 Synthesis of 2- (4- (5- (1, 4-oxazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (tert-butyl) isoxazol-5-yl) acetamide (I-37)
The desired product was obtained following a similar procedure to that for the synthesis of I-28, using intermediate 8c and 1, 4-oxazolidine.
MS:m/z:474.5(M+H)+。
EXAMPLE 38 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (3-hydroxyazetidin-1-yl) -1H-benzo [ d ] -imidazol-1-yl) phenyl) acetamide (I-38)
Following a similar procedure to that for the synthesis of I-28, using intermediate 8c and nitrogenThe target product is obtained by the heterocyclic butane-3-alcohol. MS M/z 446.5(M + H)+。
EXAMPLE 39 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (3-hydroxypyrrolidin-1-yl) -1H-benzo [ d ] -imidazol-1-yl) phenyl) acetamide (I-39)
The desired product was obtained in a similar manner to that for the synthesis of I-28, using intermediate 8c and pyrrolidin-3-ol. MS M/z 460.2(M + H) +.
EXAMPLE 40 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (4-hydroxy-4-methylpiperidin-1-yl) -1H-benzo [ d ] -imidazol-1-yl) phenyl) acetamide (I-40)
The desired product was obtained in analogy to the synthesis of I-28, using intermediate 8c and 4-methylpiperidin-4-ol.
MS:m/z:488.2(M+H)+。
Example 41: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (N-Boc-3, 6-dihydropyridin-1 (2H) -) -4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-41)
The desired product was obtained by a similar procedure to that for the synthesis of I-1, using intermediate 8c and N-Boc-1,2,5, 6-tetrahydropyridine-4-boronic acid pinacol ester (9 d).
MS:m/z:556.3(M+H)+；1H NMR(DMSO-d6,400MHz):δ＝11.86(s,1H),8.54(s,1H),7.80(s,1H),7.66-7.64(m,2H),7.59-7.55(m,4H),7.47-7.45(m,1H),6.22(s,1H),6.18(s,1H),4.04-4.02(m,2H),3.82(s,2H),3.60-3.58(m,2H),2.56-2.54(m,2H),1.44(s,9H),1.24(s,9H)。
EXAMPLE 42 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (1,2,3, 6-tetrahydropyridin) -4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-42)
Figure BDA0002888117580000301
The intermediate I-41 and trifluoroacetic acid were used according to the above route to give the desired product I-42.
MS m/z:456.2(M+H)+；1H NMR(DMSO-d6,400MHz):δ＝11.99(s,1H),9.42(s,1H),8.58(s,1H),7.86(s,1H),7.67-7.63(m,2H),7.61-7.57(m,3H),7.50-7.48(m,1H),6.23-6.22(m,1H),6.21(s,1H),3.85(s,2H),3.76-3.75(m,2H),3.33-3.32(m,2H),2.81-2.79(m,2H),1.24(s,9H).13C NMR(DMSO-d6,100MHz):δ＝172.9,168.0,161.4,144.5,135.2,135.0,134.3,133.2,131.4,123.9,121.3,116.6,111.2,86.4,45.8,42.0,41.9,32.4,29.4,24.0。
EXAMPLE 43 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (piperidin-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-43)
Figure BDA0002888117580000311
Step 1: the I-41 and Pd/C mixture was suspended in methanol and stirred overnight under hydrogen until TLC monitoring of the reaction showed complete consumption of compound I-41, the mixture was filtered through a pad of celite and the filtrate was concentrated to give compound I-41-2H.
MS m/z:558.3(M+H)+；1H NMR(DMSO-d6,400MHz):δ＝11.86(s,1H),8.50(s,1H),7.64-7.61(m,3H),7.57-7.53(m,3H),7.24-7.22(m,1H),6.22(s,1H),4.04-4.02(m,2H),3.82(s,2H),3.59-3.58(m,2H),2.56-2.54(m,2H),1.58-1.55(m,2H),1.44(s,9H),1.24(s,9H).
Step 2: to a solution of I-41-2H in methylene chloride was added CF3COOH, the reaction mixture was stirred at room temperature for 1H until TLC monitoring the reaction showed complete consumption of compound I-41-2H, and saturated NaHCO was used3Adjusting pH to 7, extracting with dichloromethane, washing the organic phase with water and brine, respectively, and extracting with anhydrous Na2SO4Drying and evaporating to obtain a crude product, and purifying by preparative TLC to obtain a compound I-43.
MS m/z:458.2(M+H)+；1H NMR(DMSO-d6,400MHz):δ＝8.52(s,1H),7.65-7.62(m,3H),7.59-7.57(m,4H),7.22-7.20(m,1H),6.06(s,1H),3.95(s,2H),3.39-3.36(m,2H),3.04-2.98(m,3H),2.00-1.89(m,4H),1.19(s,9H)。
Example 44: synthesis of ethyl 2- (4- (1- (4- (2- ((3- (tert-butyl) isoxazol-5-yl) amino) -2-oxoethyl) phenyl) -1H-benzo [ d ] imidazol-5-yl) -1H-pyrazol-1-yl) acetate (I-44)
Figure BDA0002888117580000312
The compounds I-4 and ethyl 2-bromoacetate, K were used according to the above route2CO3Obtaining the target product.
1H NMR(DMSO-d6,400MHz):δ＝11.92(s,1H),8.60(s,1H),8.28(s,1H),8.06-8.05(m,2H),7.74-7.72(m,2H),7.69-7.67(m,1H),7.64-7.61(m,3H),6.28(s,1H),5.15(s,2H),4.25-4.21(m,2H),3.88(s,2H),1.31(s,9H),1.30-1.27(t,3H)；MS m/z:527.2(M+H)+。
Example 45: synthesis of tert-butyl 2- (4- (1- (4- (2- ((3- (tert-butyl) isoxazol-5-yl) amino) -2-oxoethyl) phenyl) -1H-benzo [ d ] imidazol-5-yl) -1H-pyrazol-1-yl) acetate (I-45)
Figure BDA0002888117580000321
Using Compound I-4 and t-butyl acetate, K according to the above route2CO3Obtaining a target product I-45.
1H NMR(DMSO-d6,400MHz):δ＝11.28(s,2H),8.53(s,1H),8.21(s,1H),7.99(s,1H),7.67-7.65(m,2H),7.6-7.56(m,4H),6.59(s,1H),4.96(s,2H),3.79(s,2H),1.45(s,9H),1.29(s,9H)；MS m/z:555.2(M+H)+。
EXAMPLE 46 Synthesis of 2- (4- (1- (4- (2- ((3- (tert-butyl) isoxazol-5-yl) amino) -2-oxoethyl) phenyl) -1H-benzo [ d ] imidazol-5-yl) -1H-pyrazol-1-yl) acetic acid (I-46)
Compound I-46 is prepared using product I-45 and HCl/EA, or compound I-46 is prepared using product I-44 and LiOH hydrolysis conditions.
1HNMR(DMSO-d6,400MHz):δ＝11.28(s,1H),9.47(s,1H),8.28(s,1H),7.99(s,2H),7.71-7.69(m,4H),7.60-7.58(m,2H),6.52(s,1H),4.94(s,2H),3.78(s,2H),1.21(s,9H)；MS m/z:499.2(M+H)+。
EXAMPLE 47 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (pyrimidin-5-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-47)
Following a similar procedure to that for the synthesis of I-1, intermediate 8c and pyrimidin-5-ylboronic acid (9k) were used to afford the desired product.
MS m/z:453.2(M+H)+。
EXAMPLE 48 Synthesis of N- (3- (tert-butyl) isothiazol-5-yl) -2- (4- (5- (pyrimidin-5-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-48)
Following a similar procedure to that for the synthesis of I-1, intermediate 8z and pyrimidin-5-ylboronic acid (9k) were used to afford the desired product.
MS m/z:469.2(M+H)+。
EXAMPLE 49 Synthesis of N- (3- (tert-butyl) isothiazol-5-yl) -2- (4- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-49)
The desired product was prepared following a similar procedure to that for the synthesis of I-1, using intermediate 8z and (1-methyl-1H-pyrazol-4-yl) boronic acid (9 b).
MS m/z:471.2(M+H)+。
EXAMPLE 50 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (tert-butyl) isothiazol-5-yl) acetamide (I-50)
Following an analogous procedure to that for the synthesis of I-1, intermediate 8z and (3-4,4,5, 5-tetramethyl- [1,3, 2)]Dioxolan-2-yl) -pyrazole-1-carboxylic acid tert-butyl ester (10c) preparation of the expected product. MS M/z 457.2(M + H)+。
EXAMPLE 51 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3-methylisothiazol-5-yl) acetamide (I-51)
The title product was prepared in analogy to the synthesis of I-1, using intermediate 8aa and tert-butyl (3-4,4,5, 5-tetramethyl- [1,3,2] dioxolan-2-yl) -pyrazole-1-carboxylate (10 c).
MS m/z:415.1(M+H)+。
EXAMPLE 52 Synthesis of 2- (4- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3-methylisothiazol-5-yl) acetamide (I-52)
The desired product was prepared following a similar procedure to that for synthesis of I-1, using intermediate 8aa and (1-methyl-1H-pyrazol-4-yl) boronic acid (9 b).
MS m/z:429.1(M+H)+。
EXAMPLE 53 Synthesis of N- (3- (4-chlorophenyl) -1-methyl-1H-pyrazol-5-yl) -2- (4- (5- (1-methyl-1H) -pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-53)
The desired product was prepared following a similar procedure to that for the synthesis of I-1, using intermediate 8bb and (1-methyl-1H-pyrazol-4-yl) boronic acid (9 b).
MS m/z:522.2(M+H)+。
EXAMPLE 54 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (4) -chlorophenyl) -1-methyl-1H-pyrazol-5-yl) acetamide (I-54)
The desired product was obtained in analogy to the synthesis of I-1, using intermediate 8bb and tert-butyl (3-4,4,5, 5-tetramethyl- [1,3,2] dioxolan-2-yl) -pyrazole-1-carboxylate (10 c).
MS m/z:508.2(M+H)+。
EXAMPLE 55 Synthesis of 2- (4- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3-methyl-1H-pyrazol-5-yl) acetamide (I-55)
The desired product was prepared following a similar procedure to that for the synthesis of I-1, using intermediate 8cc and (1-methyl-1H-pyrazol-4-yl) boronic acid (9 b).
MS m/z:412.2(M+H)+。
EXAMPLE 56 Synthesis of N- (3- (tert-butyl) -1H-pyrazol-5-yl) -2- (4- (5- (pyridin-3-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-56)
Following a similar procedure to that for the synthesis of I-1, using intermediate 8dd preparation and pyridin-3-ylboronic acid (9g) gave the desired product.
MS m/z:451.2(M+H)+。
EXAMPLE 57 Synthesis of N- (3- (tert-butyl) -1H-pyrazol-5-yl) -2- (4- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-57)
Following an analogous procedure to that for the synthesis of I-1, intermediate 8dd was used to prepare and the (1-methyl-1H-pyrazol-4-yl) boronic acid (9b) gave the desired product.
MS m/z:454.2(M+H)+。
EXAMPLE 58 Synthesis of 2- (4- (5- (1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (tert-butyl) -1-methyl-1H-pyrazol-5-yl) acetamide (I-58)
The desired product is obtained analogously to the synthesis of I-1, using intermediate 8ee and tert-butyl (3-4,4,5, 5-tetramethyl- [1,3,2] dioxolan-2-yl) -pyrazole-1-carboxylate (10 c).
MS m/z:454.2(M+H)+。
EXAMPLE 59 Synthesis of N- (3- (tert-butyl) -1-methyl-1H-pyrazol-5-yl) -2- (4- (5- (1-methyl-1H-pyrazol) -4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-59)
The title product was prepared in analogy to the synthesis of I-1, using intermediate 8ee and (1-methyl-1H-pyrazol-4-yl) boronic acid (9 b).
MS m/z:468.2(M+H)+。
EXAMPLE 60 Synthesis of N- (3- (tert-butyl) -1-methyl-1H-pyrazol-5-yl) -2- (4- (5- (pyridin-3-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-60)
The desired product was obtained in analogy to the synthesis of I-1, using intermediate 8ee and pyridin-3-ylboronic acid (9 g).
MS m/z:465.2(M+H)+。
Example 61: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (pyridin-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-61)
The desired product was obtained in analogy to the synthesis of I-1, using intermediate 8c and pyridin-4-ylboronic acid (9 e).
MS m/z:452.5(M+H)+。
EXAMPLE 62 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (pyridin-3-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-62)
Following a similar procedure to that for the synthesis of I-1, intermediate 8c and pyridin-3-ylboronic acid (9g) were used to afford the desired product.
MS m/z:452.5(M+H)+；1H NMR(DMSO-d6,400MHz):δ＝8.97(s,1H),8.63(s,1H),8.57-8.56(m,1H),8.16-8.14(m,2H),7.75-7.68(m,4H),7.60-7.58(m,2H),7.51-7.48(m,1H),6.23(s,1H),3.84(s,2H),1.24(s,9H).13C NMR(DMSO-d6,100MHz):δ＝172.9,167.9,161.3,148.4,148.3,145.0,144.7,136.5,135.1,135.0,134.7,133.5,132.3,131.3,124.3,124.0,123.2,118.7,111.8,86.4,42.1,32.4,29.4。
EXAMPLE 63 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (pyridin-2-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-63)
The desired product was obtained in analogy to the synthesis of I-1, using intermediate 8c and pyridin-2-ylboronic acid (9 f).
MS m/z:452.5(M+H)+。
EXAMPLE 64 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (6-methylpyridin-3-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-64)
Following a similar procedure to that for the synthesis of I-1, intermediate 8c and (6-methylpyridin-3-yl) boronic acid (9h) were used to give the desired product.
MS m/z:466.2(M+H)+。
EXAMPLE 65 Synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (6-methoxypyridin-3-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-65)
The desired product was obtained in analogy to the synthesis of I-1, using intermediate 8c and (6-methoxypyridin-3-yl) boronic acid (9I).
MS m/z:482.2(M+H)+。
Example 66: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (5- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) thiophen-2-yl) acetamide (I-66)
The desired product was prepared according to a similar procedure to that for the synthesis of I-1, using intermediate 8gg and N-methylpyrazole boronic acid (9 b).
MS m/z:461.2(M+H)+。
Example 67: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (7- (1-methyl-1H-pyrazol-4-yl) imidazo [1,2a ] pyridin-3-yl) phenyl) acetamide (I-67)
Figure BDA0002888117580000351
Compound 33 was synthesized using commercially available 2-amino-4-bromopyridine with ethyl 2- (3- (1-bromo-2-oxoethyl) phenylacetate under the conditions referred to CN104650076 and WO2012007345, and the first and second steps used intermediate 35 prepared by a method analogous to that for synthesizing compound 6 or 8, and then the target product was prepared using intermediate 35 and N-methylpyrazole boronic acid (9b) according to a method analogous to that for synthesizing I-1.
MS m/z:455.2(M+H)+。
Example 68: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (6- (1-methyl-1H-pyrazol-4-yl) pyrazolo [1,5a ] pyrimidin-3-yl) phenyl) acetamide (I-68)
Figure BDA0002888117580000361
Compound 36 was prepared according to the procedure of CN108484608 using commercially available 6-bromo-3-iodo-pyrazolo [1,5-a ] pyrimidine and linalool (4-ethoxycarbonyltolyl) borate as starting materials, then intermediate 38 prepared according to the procedure analogous to the synthesis of compound 6 or 8 was used with compound 36, and then the desired product was prepared according to the procedure analogous to the synthesis of I-1 using intermediate 38 and N-methylpyrazole boronic acid (9 b).
MS m/z:456.2(M+H)+。
Example 69: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (6- (1-methyl-1H-pyrazol-4-yl) pyrazolo [1,5a ] pyrazin-3-yl) phenyl) acetamide (I-69)
Figure BDA0002888117580000362
Compound 39 was prepared using commercially available 2-bromo-5-iodopyrazine and pinacol (4-ethoxycarbonyltolyl) borate as starting materials with reference to the method of WO2008078091, intermediate 41 prepared in the first and second steps using a method similar to that for the synthesis of compound 6 or 8, and then the target product was prepared using intermediate 41 and N-methylpyrazole boronic acid (9b) with reference to a method similar to that for the synthesis of I-1.
MS m/z:456.2(M+H)+。
Example 70: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (7- (1-methyl-1H-pyrazol-4-yl) imidazo [1,2b ] pyridazin-3-yl) phenyl) acetamide (I-70)
The objective product was prepared by a similar method to that of example 68 using commercially available 7-chloro-3-iodoimidazo (1,2-B) pyrazine as a starting material.
MS m/z:456.2(M+H)+。
Example 71: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- ((2- (2-methoxyethoxy) ethyl) (methyl) amino) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-71)
This compound was prepared in a similar manner to the synthesis of compound I-31, using intermediate 8c and 2- (2-methoxyethoxy) -N-methylethyl-1-amine to give the desired product.
MS m/z:506.3(M+H)+。
Example 72: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- ((3- (dimethylamino) propyl) (methyl) amino) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-72)
This compound was prepared in a similar manner to the synthesis of compound I-31, using intermediate 8c and N, N, N' -trimethylethylenediamine to give the desired product.
MS m/z:489.3(M+H)+。
Example 73: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- ((3-methoxypropyl) (methyl) amino) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-73)
This compound was prepared in a similar manner to the synthesis of compound I-31, using intermediate 8c and 3-methoxy-N-methyl-1-propylamine to give the desired product.
MS m/z:476.3(M+H)+。
Example 74: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- ((2-methoxyethyl) (methyl) amino) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-74)
This compound was prepared in a similar manner to the synthesis of compound I-31, using intermediate 8c and 2-methoxy-N-methylethan-1-amine to give the desired product.
MS m/z:462.2(M+H)+。
Example 75: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- ((2-hydroxyethyl) (methyl) amino) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-75)
This compound was prepared in a similar manner to the synthesis of compound I-31, using intermediate 8c and 2- (methylamino) ethan-1-ol to give the desired product.
MS m/z:448.2(M+H)+。
Example 76: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) 2- (4- (5- (piperidine-4-acylamino) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-76)
This compound was prepared in a similar manner to the synthesis of compound I-31, using intermediate 8c and piperidin-4-amine to give the desired product.
MS m/z:473.3(M+H)+。
Example 77: synthesis of 2- (4- (5- (2-azaspiro [3.3] heptan-2-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (tert-butyl) -isoxazol-5-yl) acetamide (I-77)
This compound was prepared in a similar manner to the synthesis of compound I-31 using intermediate 8c and 2-azaspiro [3.3] heptane hydrochloride to afford the desired product.
MS m/z:470.3(M+H)+。
Example 78: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (6-hydroxy-6-methyl-2-azaspiro [3.3] heptan-2-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-78)
This compound was prepared according to a similar method to that for the synthesis of compound I-31, using intermediate 8c and 6-methyl-2-azaspiro [3.3] heptane-6-ol hydrochloride to give the desired product.
MS m/z:500.3(M+H)+。
Example 79: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (2- (3-methoxypropoxy) -ethoxy) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-79)
This compound was prepared in a similar manner to the synthesis of compound I-31, using intermediate 8c and 2- (3-methoxypropoxy) ethan-1-ol to give the desired product.
MS m/z:507.3(M+H)+。
Example 80: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2-methyl-2 (4- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) propanamide (I-80)
This compound was prepared in a similar manner to the synthesis of compound I-1, using intermediate 8ff and N-methylpyrazole boronic acid (9b) to prepare the desired product.
MS m/z:483.2(M+H)+。
Example 81: (E) synthesis of (E) -N- (3- (tert-butyl) isoxazol-5-yl) -2- (4- (5- (3-hydroxypropyl-1-en-1-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-81)
This compound was prepared in a similar manner to the synthesis of compound I-31, using intermediate 8c and trans-3-hydroxypropylboronic acid pinacol ester to give the desired product.
MS m/z:431.2(M+H)+。
Example 82: synthesis of N- (3 (tert-butyl) isoxazol-5-yl) -2- (4- (5- (3-hydroxypropyl-1-yn-1-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-82)
This compound was prepared in a similar manner to the synthesis of compound I-31, using intermediate 8c and propynyloxytrimethylsilane to give the desired product.
MS m/z:429.2(M+H)+。
Example 83: synthesis of 2- (4- (5- (2,6 diazaspiro [3.3] heptan-2-yl) -1H-benzo [ d ] imidazol-1-yl) phenyl) -N- (3- (tert-butyl) isoxazol-5-yl) acetamide (I-83)
This compound was prepared in a similar manner to the synthesis of compound I-31 using intermediate 8c and tert-butyl 2, 6-diazaspiro [3.3] heptane-2-carboxylate to afford the desired product.
MS m/z:471.2(M+H)+。
Example 84: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (6- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) pyridazin-3-yl) acetamide (I-84)
This compound was prepared in a similar manner to the synthesis of compound I-1, using intermediate 8hh and N-methylpyrazole boronic acid (9b) to prepare the desired product.
MS m/z:457.2(M+H)+。
Example 85: synthesis of N- (3- (tert-butyl) isoxazol-5-yl) -2- (5- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [ d ] imidazol-1-yl) pyrimidin-2-yl) acetamide (I-85)
This compound was prepared in a similar manner to the synthesis of compound I-1, using intermediate 8ii and N-methylpyrazole boronic acid (9b) to prepare the desired product.
MS m/z:457.2(M+H)+。
Example 86: synthesis of N- (3-isopropylisoxazol-5-yl) -2- (4- (5-morpholinyl-1H-benzo [ d ] imidazol-1-yl) phenyl) acetamide (I-86)
This compound was prepared in a similar manner to the synthesis of compound I-31, using intermediate 8d and morpholine to give the desired product.
1H NMR(400MHz,CDCl3)δ8.37(s,1H),7.99(s,1H),7.45(m,4H),7.39(d,1H),7.31(s,1H),7.01(d,1H),6.23(s,1H),3.88–3.82(m,4H),3.80(s,2H),3.16–3.08(m,4H),2.93(m,1H),1.20(d,6H)。MS m/z:446.4(M+H)+。
Example 87: study of biological Activity
The in vitro inhibitory activity of some compounds of the invention against 4 enzymes was determined using the mobility transfer method, as follows:
kinase buffer was prepared at 1-fold concentration. The compounds were serially diluted in 3-fold gradient with dimethyl sulfoxide at 10 concentrations (100000,33333.33,11111.11, 3703.70,1234.57,411.52,137.17,45.72,15.24, 5.08nM, respectively) to make 100-fold final solutions. The final starting concentration of test compound was 1mM (1000 nM).
The control was serially diluted in 3-fold gradient with dimethyl sulfoxide at 10 concentrations (100000,33333.33,11111.11, 3703.70,1234.57,411.52,137.17,45.72,15.24, 5.08nM) to make 100-fold final solution.
Using a dispenser Echo550 to 384 microporous transfer 250nL100 times the final concentration of the test compounds. A kinase solution with a final concentration of 2.5 times was prepared by diluting with a kinase buffer solution with a concentration of 1 time. Mu.l of a 2.5 fold final concentration kinase solution was added to 384 microwell plates. mu.L of 1-fold concentration kinase buffer was added to the negative control wells. The enzyme and test compound were pre-incubated for 10 minutes at room temperature. A mixed solution of ATP and substrate at a final concentration of 5/3 times was prepared using 1-fold kinase buffer. mu.L of a mixed solution of ATP and substrate at 5/3-fold final concentration was added to a 384-well plate and reacted at room temperature. The reaction was stopped by adding 30. mu.L of stop buffer.
The conversion was read using Caliper EZReader II. The data analysis method is as follows:
(1) % Inh ═ 100 (max signal-composite signal)/(max signal-min signal).
(2) In the absence of compound, the maximum signal was obtained.
(3) Minimal signal was obtained in the absence of enzyme.
Table 3 lists the IC's of several test compounds against several kinases50The value is obtained.
TABLE 3 results of in vitro kinase inhibition assay with different compounds
Figure BDA0002888117580000401
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, it should be noted that, for those skilled in the art, many modifications and variations can be made without departing from the technical principle of the present invention, and these modifications and variations should also be regarded as the protection scope of the present invention.

Claims (10)

1. A5-aminoisoxazole derivative is characterized in that the structural formula is shown as a formula I:
Figure FDA0002888117570000011
wherein:
a is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and the substituent on the substituted aryl or substituted heteroaryl is selected from substituted or unsubstituted C1-10Alkyl, substituted or unsubstituted C1-10One or more of alkoxy, halogen and nitrile group;
b is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a group of formula (II), substituted or unsubstituted saturated or unsaturated C3-10Cycloalkyl or a heteroatom substituted or unsubstituted 4-7 membered cyclic amine; wherein the content of the first and second substances,
the substituents on the substituted aryl or substituted heteroaryl are selected from C1-10Alkyl radical, C1-10One or more of alkoxy, carboxyl, ester group, sulfone group and sulfonamide group;
the group of formula (II) is as follows:
Figure FDA0002888117570000012
wherein R is3And R4Each independently selected from hydrogen and C1-10Alkyl radical, C1-10Alkoxy radical, C1-10Alkylamino radical or C1-6A hydroxyalkyl group;
or R3And R4Linked to form a ring to form a substituted C3-10Cycloalkyl, said substituted C3-10Cycloalkyl includes heteroatom-substituted cycloalkyl or a spiro carbocyclic ring containing NH and/or oxygen atoms;
4-7 membered cyclic amine substituted or unsubstituted by hetero atom is chiral molecule or achiral molecule;
R1selected from hydrogen, substituted or unsubstituted C1-10An alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; the substituents on the substituted aryl or substituted heteroaryl groups are selected from substituted or unsubstituted C1-10Alkyl, substituted or unsubstituted C1-10One or more of alkoxy, halogen and halogen;
R2selected from hydrogen, C1-3Alkyl, cyanoBase, C1-3Fluoroalkyl or halogen;
W1、W2、W3、W4、W5、W6and W7Each being CH or N, satisfying the valence state, and at least W1、W2、W3、W4、W5、W6And W7One of them is N;
W8o, S, NH or NMe;
y is selected from a group of the following structural formula:
Figure FDA0002888117570000021
2. a 5-aminoisoxazole derivative according to claim 1 characterized in that: in the A or B group, the aryl group is C6-C9Aryl, heteroaryl including C with nitrogen and/or sulfur as hetero atoms4-C6A heteroaryl group.
3. A 5-aminoisoxazole derivative according to claim 1 characterized in that: a is selected from a group of the following structural formula:
Figure FDA0002888117570000022
4. a 5-aminoisoxazole derivative according to claim 1 wherein B is selected from a group of the following formulae:
Figure FDA0002888117570000023
5. the 5-aminoisoxazole derivative of claim 1 wherein R is1Is selected from one of the following knotsA group of formula (la):
Figure FDA0002888117570000031
6. a 5-aminoisoxazole derivative according to claim 1 having the formula shown in one of formulae I-1 to I-86:
Figure FDA0002888117570000032
Figure FDA0002888117570000041
Figure FDA0002888117570000051
Figure FDA0002888117570000061
Figure FDA0002888117570000071
7. a pharmaceutical formulation characterized by: comprising the 5-aminoisoxazole derivative of any one of claims 1 to 6, or a pharmaceutically acceptable salt, stereoisomer, deuterium substituted derivative, hydrate or solvate thereof.
8. Use of a 5-aminoisoxazole derivative of any one of claims 1 to 6, or a pharmaceutically acceptable salt, stereoisomer, deuterium substituted derivative, hydrate or solvate thereof, in the manufacture of a medicament for the treatment of a condition which can be ameliorated or prevented by inhibition of kinase activity or inhibition of cell or enzyme proliferation; the kinases include one or more of FLT1, FLT3, FLT4, FGFR1-4, VEGFR2/KDR, PDGFRa, PDGFRb and cKit kinases.
9. Use according to claim 8, wherein the condition is selected from cancer and/or immune-related diseases.
10. The use according to claim 8, wherein the medicament is administered orally, parenterally, intravenously or transdermally.
CN202110019871.8A 2021-01-07 2021-01-07 5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor Pending CN112778294A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202110019871.8A CN112778294A (en) 2021-01-07 2021-01-07 5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor
CN202110626578.8A CN113321645A (en) 2021-01-07 2021-06-04 5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor
PCT/CN2021/135715 WO2022148196A1 (en) 2021-01-07 2021-12-06 Multikinase inhibitor and use thereof
CN202210018194.2A CN114195771A (en) 2021-01-07 2022-01-07 Multi-kinase inhibitors and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110019871.8A CN112778294A (en) 2021-01-07 2021-01-07 5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor

Publications (1)

Publication Number Publication Date
CN112778294A true CN112778294A (en) 2021-05-11

Family

ID=75756049

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110019871.8A Pending CN112778294A (en) 2021-01-07 2021-01-07 5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor
CN202110626578.8A Pending CN113321645A (en) 2021-01-07 2021-06-04 5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor
CN202210018194.2A Pending CN114195771A (en) 2021-01-07 2022-01-07 Multi-kinase inhibitors and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110626578.8A Pending CN113321645A (en) 2021-01-07 2021-06-04 5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor
CN202210018194.2A Pending CN114195771A (en) 2021-01-07 2022-01-07 Multi-kinase inhibitors and uses thereof

Country Status (2)

Country Link
CN (3) CN112778294A (en)
WO (1) WO2022148196A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113321645A (en) * 2021-01-07 2021-08-31 苏州安睿药业有限公司 5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000051A (en) * 2005-02-24 2006-08-31 Lilly Co Eli VEGF-R2 INHIBITORS AND METHODS
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US9988371B2 (en) * 2014-06-03 2018-06-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Benzimidazole analogues and related methods
AU2020355359B2 (en) * 2019-09-26 2023-08-24 Shenzhen Targetrx, Inc. Substituted aromatic fused ring derivative and composition comprising same, and use thereof
CN112778294A (en) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113321645A (en) * 2021-01-07 2021-08-31 苏州安睿药业有限公司 5-aminoisoxazole derivative and application thereof in preparation of multi-kinase inhibitor
CN114195771A (en) * 2021-01-07 2022-03-18 苏州安睿药业有限公司 Multi-kinase inhibitors and uses thereof
WO2022148196A1 (en) * 2021-01-07 2022-07-14 苏州安睿药业有限公司 Multikinase inhibitor and use thereof

Also Published As

Publication number Publication date
WO2022148196A1 (en) 2022-07-14
CN114195771A (en) 2022-03-18
CN113321645A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
KR102594476B1 (en) Aminothiazole compounds as C-KIT inhibitors
JP7023243B2 (en) Isoquinoline-3 yl-carboxamide and its preparation and method of use
JP7368369B2 (en) Heterocyclic compounds as PRMT5 inhibitors
TWI545122B (en) Pyrazolyl quinoxaline kinase inhibitors
CN106928219B (en) Nitrogen-containing fused heterocyclic compound, preparation method, intermediate, composition and application
CN108349896B (en) Heterocyclic compounds as FGFR inhibitors
JP2022530383A (en) Quinazoline compounds and their pharmaceutical uses
CN113316576A (en) 2, 3-dihydro-1H-pyrrolo [3,4-c ] pyridin-1-one derivatives as HPK1 inhibitors for the treatment of cancer
JP6122877B2 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin activating enzyme
WO2020107987A1 (en) Erk inhibitor containing isoindoline, preparation method therefor and application thereof
CN113387962A (en) Pyrazolo [3,4-d ] pyrimidine-3-one derivative, pharmaceutical composition and application thereof
JP2022502455A (en) Indolinone compounds for use as MAP4K1 inhibitors
JP2015508775A5 (en)
CN110520416B (en) Polysubstituted pyridone derivative, preparation method and medical application thereof
Xu et al. Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3, 3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors
WO2020186220A1 (en) Compounds as inhibitors of macrophage migration inhibitory factor
JP2024505765A (en) CDK6/DYRK2 dual target inhibitor and its production method and application
CN114195771A (en) Multi-kinase inhibitors and uses thereof
CN104703599A (en) Aminoisoquinoline derivatives as protein kinase inhibitors
WO2022017434A1 (en) Compound having kinase inhibitory activity
TWI705965B (en) Novel tricyclic compounds
CN114437074A (en) Compound, pharmaceutical composition containing compound and application of compound
WO2023178928A1 (en) 2-amino-4-indolyl pyrimidine compounds, preparation method therefor and uses thereof
WO2019085996A1 (en) Pyridopyrimidine compounds acting as mtorc 1/2 double-kinase inhibitors
WO2020233645A1 (en) Macrolide derivatives, preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210511

WD01 Invention patent application deemed withdrawn after publication